Reuters: Regulatory News: FDA approves Abbott's Humira for ulcerative colitis

Reuters: Regulatory News Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com

FDA approves Abbott's Humira for ulcerative colitis Sep 28th 2012, 17:59 Sept 28 | Fri Sep 28, 2012 1:59pm EDT Sept 28 (Reuters) - U.S health regulators on Friday approved Abbott Laboratories Inc's blockbuster rheumatoid arthritis drug Humira for the treatment of moderate to severe ulcerative colitis in adults. The U.S. Food and Drug Administration approved Humira to control the chronic inflammatory condition once immunosuppressant medicines, such as corticosteroids, have proved ineffective. Humira, by far Abbott's biggest product with annual sales of about $8 billion and still growing, is already approved to treat a number of inflammatory diseases. In addition to rheumatoid arthritis, the medicine is approved for psoriatic arthritis, ankylosing spondylitis, Crohn's disease, plaque psoriasis and juvenile idiopathic arthritis.

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions